The stock price of Twist Bioscience Corp (NASDAQ: TWST) has dropped by -2.38 compared to previous close of 31.50. Despite this, the company has seen a gain of 7.63% in its stock price over the last five trading days. Business Wire reported 2024-04-18 that SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it will issue its financial results for the fiscal 2024 second quarter ended March 31, 2024, after market close on Thursday, May 2, 2024. The company plans to hold a conference call and live audio webcast for analysts and investors at 4:30 p.m. Eastern Time to discuss.
Is It Worth Investing in Twist Bioscience Corp (NASDAQ: TWST) Right Now?
The 36-month beta value for TWST is at 1.63. Analysts have varying views on the stock, with 1 analysts rating it as a “buy,” 1 rating it as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for TWST is 55.30M, and currently, shorts hold a 22.17% of that float. The average trading volume for TWST on April 25, 2024 was 882.35K shares.
TWST’s Market Performance
TWST stock saw a decrease of 7.63% in the past week, with a monthly decline of -10.17% and a quarterly a decrease of -5.88%. The volatility ratio for the week is 5.86%, and the volatility levels for the last 30 days are 4.91% for Twist Bioscience Corp (TWST). The simple moving average for the past 20 days is -2.90% for TWST’s stock, with a 11.91% simple moving average for the past 200 days.
Analysts’ Opinion of TWST
Many brokerage firms have already submitted their reports for TWST stocks, with Goldman repeating the rating for TWST by listing it as a “Buy.” The predicted price for TWST in the upcoming period, according to Goldman is $45 based on the research report published on January 17, 2024 of the current year 2024.
Berenberg, on the other hand, stated in their research note that they expect to see TWST reach a price target of $27. The rating they have provided for TWST stocks is “Buy” according to the report published on September 27th, 2023.
Scotiabank gave a rating of “Sector Outperform” to TWST, setting the target price at $33 in the report published on January 05th of the previous year.
TWST Trading at -12.64% from the 50-Day Moving Average
After a stumble in the market that brought TWST to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -28.84% of loss for the given period.
Volatility was left at 4.91%, however, over the last 30 days, the volatility rate increased by 5.86%, as shares sank -8.89% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -24.28% lower at present.
During the last 5 trading sessions, TWST rose by +7.63%, which changed the moving average for the period of 200-days by +43.62% in comparison to the 20-day moving average, which settled at $31.52. In addition, Twist Bioscience Corp saw -16.58% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at TWST starting from Laponis Adam, who sale 556 shares at the price of $33.16 back on Apr 09 ’24. After this action, Laponis Adam now owns 74,444 shares of Twist Bioscience Corp, valued at $18,434 using the latest closing price.
Leproust Emily M., the Chief Executive Officer of Twist Bioscience Corp, sale 1,132 shares at $32.74 during a trade that took place back on Apr 02 ’24, which means that Leproust Emily M. is holding 514,149 shares at $37,057 based on the most recent closing price.
Stock Fundamentals for TWST
Current profitability levels for the company are sitting at:
- -0.84 for the present operating margin
- 0.36 for the gross margin
The net margin for Twist Bioscience Corp stands at -0.78. The total capital return value is set at -0.33. Equity return is now at value -30.80, with -25.06 for asset returns.
Based on Twist Bioscience Corp (TWST), the company’s capital structure generated 0.13 points at debt to capital in total, while cash flow to debt ratio is standing at -1.21. The debt to equity ratio resting at 0.16. The interest coverage ratio of the stock is -55175.5.
Currently, EBITDA for the company is -193.21 million with net debt to EBITDA at 0.96. When we switch over and look at the enterprise to sales, we see a ratio of 6.03. The receivables turnover for the company is 7.42for trailing twelve months and the total asset turnover is 0.36. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.98.
Conclusion
In conclusion, Twist Bioscience Corp (TWST) has had a mixed performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
